Breakthrough Pediatric HIV Treatment Receives Tentative USFDA Approval

44
USFDA Approval

Last Updated on September 16, 2023 by The Health Master

HIV Treatment

In a significant stride towards pediatric HIV treatment, Viatris Inc. has garnered tentative approval from the US Food and Drug Administration (USFDA) for a groundbreaking new drug application.

This development heralds the advent of abacavir 60 mg, dolutegravir 5 mg, and lamivudine 30 mg tablets for oral suspension, designed to combat HIV-1 infection in pediatric patients.

Revolutionizing Pediatric HIV Treatment

Historical Challenges Addressed

Treating pediatric HIV patients has long been a challenge due to the specialized formulations required for children.

The fixed-dose combination of abacavir 60 mg, dolutegravir 5 mg/lamivudine 30 mg tablets for oral suspension comes in a strawberry-flavored solution, making it a palatable option for young patients.

PEPFAR Program Assurance

The USFDA’s tentative approval under the President’s Emergency Plan for AIDS Relief (PEPFAR) program attests to the formulation’s adherence to the highest quality, safety, and efficacy standards.

This milestone assures that the new drug meets all regulatory criteria.

Collaborative Efforts for Global Impact

Partnerships for Progress

Viatris has strategically partnered with key players to ensure the widespread production and distribution of this revolutionary treatment.

Licensing agreements with the Medicines Patent Pool (MPP) and a development pact with ViiV Healthcare (ViiV) and the Clinton Health Access Initiative (CHAI) solidify the commitment to pediatric healthcare.

A Game-Changer for Children Living with HIV

Rakesh Bamzai, President of India, Emerging Asia, and Access Markets at Viatris, expressed enthusiasm about the approval, emphasizing how the single tablet regimen will significantly alleviate the pill burden for children afflicted by HIV.

Sustainable Goals in HIV Care

Empowering Future Generations

This achievement aligns seamlessly with Viatris’ ambitious sustainability goal.

The company aims to provide Antiretroviral (ARV) therapy to a staggering 30 million patients by the end of 2025.

Of this, over two million are children grappling with HIV/AIDS, promising a brighter and healthier future.

Tailored Treatment for Pediatric Patients

Targeted Dosage

The fixed-dose combination of abacavir, dolutegravir/lamivudine is specifically tailored for pediatric patients weighing at least six kg up to <25 kg with HIV-1 infection.

The dosage is determined based on the patient’s weight, ensuring precise and effective treatment.

Important Considerations

It’s crucial to note that this treatment is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLAB*5701-positive patients.

These considerations are paramount to ensuring patient safety.

Global Reach for Maximum Impact

The tentative USFDA approval paves the way for regulatory authority submissions, large-scale production, and distribution across 123 low- and middle-income countries, in strict accordance with the license agreement.

This global reach promises to transform the landscape of pediatric HIV care on a grand scale.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

DCC proposes crucial amendments for enhancing Drug Regulation

USFDA Approval granted for Generic Sevelamer Carbonate Oral Suspension

Drug alert: DCGI issues alerts on two Falsified Drugs

Nutraceuticals in India: A step towards empowering Pharma Industry

DCC recommends Transparent Packaging for Eye Drops

USFDA approval granted for Generic Pirfenidone Capsules

Natco Pharma faces Antitrust Lawsuit over generic Cancer Drug

Vitamin B17: Unmasking the Controversial Cancer cure Myth

USFDA issued EIR to Aurobindo Pharma: Telangana

Drug alert: 7 drugs identified as NSQ in Rajasthan

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news